-
Rapport Therapeutics recently presented new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures at the 2025 American Epilepsy Society Meeting, showing consistent clinical benefits, including reductions in seizure severity and improvements in patient-reported outcomes, alongside PET evidence of target engagement in key brain regions.
-
The company now plans an end-of-Phase 2 meeting with the FDA this quarter and is preparing two pivotal Phase 3 trials for RAP-219 in 2026, underscoring its ambition to advance the asset beyond epilepsy into bipolar mania and diabetic peripheral neuropathic pain.
-
With RAP-219 showing consistent efficacy across disease severity and Rapport preparing for pivotal trials, we’ll examine how this shapes its investment narrative.
Find companies with promising cash flow potential yet trading below their fair value.
For Rapport Therapeutics, the big-picture belief is that RAP-219 can anchor a focused neurology platform, despite zero revenue and persistent losses. The AES data do not radically change that story, but they do strengthen a key near-term catalyst: the upcoming end-of-Phase 2 FDA meeting, which now rests on a more complete efficacy, safety, and PET target-engagement package. With shares already up sharply this quarter, the bar for future data and regulatory feedback may be higher, and any shift in FDA feedback or Phase 3 design could matter more than before. At the same time, the core risks remain: a single lead asset, a long runway to potential commercialization, continuing cash burn after the US$250,000,000 raise, and shareholder dilution already in the rear-view mirror.
Although the data help the story, one funding and dilution risk still stands out for investors.
Our valuation report unveils the possibility Rapport Therapeutics’ shares may be trading at a premium.
The Simply Wall St Community currently offers 1 RAP-219 fair value view, clustered around US$51.50 per share, underscoring how even a single estimate can sit well above today’s price. Set that against the company’s ongoing cash burn and dependence on successful FDA dialogue, and you start to see why exploring multiple viewpoints on risk, timelines and dilution pressure could matter for your own conclusions.
Explore another fair value estimate on Rapport Therapeutics – why the stock might be worth as much as 75% more than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.